PAR Stock Overview
Develops, manufactures, and sells active pharmaceutical ingredients (APIs) and fine chemicals in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Par Drugs and Chemicals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹281.40 |
| 52 Week High | ₹325.00 |
| 52 Week Low | ₹190.15 |
| Beta | 0.15 |
| 11 Month Change | 26.68% |
| 3 Month Change | 18.93% |
| 1 Year Change | 23.04% |
| 33 Year Change | 40.77% |
| 5 Year Change | 1,176.19% |
| Change since IPO | 1,015.56% |
Recent News & Updates
Recent updates
There's No Escaping Par Drugs and Chemicals Limited's (NSE:PAR) Muted Earnings Despite A 26% Share Price Rise
Oct 29
Improved Earnings Required Before Par Drugs and Chemicals Limited (NSE:PAR) Stock's 29% Jump Looks Justified
Apr 16Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today
Apr 05Do Par Drugs and Chemicals' (NSE:PAR) Earnings Warrant Your Attention?
Nov 03If EPS Growth Is Important To You, Par Drugs and Chemicals (NSE:PAR) Presents An Opportunity
May 19Does Par Drugs and Chemicals (NSE:PAR) Deserve A Spot On Your Watchlist?
Mar 17Do Par Drugs and Chemicals's (NSE:PAR) Earnings Warrant Your Attention?
Oct 22Investors Shouldn't Be Too Comfortable With Par Drugs and Chemicals' (NSE:PAR) Robust Earnings
Aug 11Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Is Well Worth Watching
Jul 14Is Par Drugs and Chemicals Limited (NSE:PAR) An Attractive Dividend Stock?
Mar 31Are Strong Financial Prospects The Force That Is Driving The Momentum In Par Drugs and Chemicals Limited's NSE:PAR) Stock?
Mar 05Chairman of the Board & MD Falgun Savani Just Bought A Handful Of Shares In Par Drugs and Chemicals Limited (NSE:PAR)
Feb 06
Here's Why I Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today
Jan 10How Does Par Drugs and Chemicals Limited (NSE:PAR) Fare As A Dividend Stock?
Dec 13Shareholder Returns
| PAR | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 3.8% | -0.2% | 0.3% |
| 1Y | 23.0% | 40.5% | 27.3% |
Return vs Industry: PAR underperformed the Indian Pharmaceuticals industry which returned 40.5% over the past year.
Return vs Market: PAR underperformed the Indian Market which returned 27.3% over the past year.
Price Volatility
| PAR volatility | |
|---|---|
| PAR Average Weekly Movement | 9.2% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in IN Market | 9.2% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: PAR's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: PAR's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1982 | 122 | Jignesh Savani | www.pardrugs.com |
Par Drugs and Chemicals Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) and fine chemicals in India. The company provides API products, including magnesium hydroxide, magnesium oxide USP, sucralfate, almagate BP, dried aluminium hydroxide gel, light magnesium carbonate, magaldrate, magnesium trisilicate, colloidal silicon dioxide, aluminium magnesium silicate, magnesium aluminometasilicate, magnesium aluminosilicate-USP, magnesium oxide light, magnesium oxide heavy, magnesium aluminium hydrate, hydrotalcite, and synthetic aluminium silicate. It offers fine chemicals, such as precipitated silica, sodium aluminium silicate, amorphous aluminium hydroxide, PARSIL-HT, PAR ADD OP, MagSil OF, FlowSil, aluminium hydroxide magnesium carbonate co-dried gel, magnesium aluminium silicate hydrated (pharma), and magnesium aluminium silicate hydrated (agro).
Par Drugs and Chemicals Limited Fundamentals Summary
| PAR fundamental statistics | |
|---|---|
| Market cap | ₹3.46b |
| Earnings (TTM) | ₹182.71m |
| Revenue (TTM) | ₹1.04b |
19.0x
P/E Ratio3.3x
P/S RatioIs PAR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PAR income statement (TTM) | |
|---|---|
| Revenue | ₹1.04b |
| Cost of Revenue | ₹355.18m |
| Gross Profit | ₹685.63m |
| Other Expenses | ₹502.92m |
| Earnings | ₹182.71m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 14.85 |
| Gross Margin | 65.87% |
| Net Profit Margin | 17.55% |
| Debt/Equity Ratio | 0% |
How did PAR perform over the long term?
See historical performance and comparison